Literature DB >> 6958308

Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies.

M R Price, M V Pimm, R W Baldwin.   

Abstract

Two mouse monoclonal antibodies against the human osteogenic sarcoma 791T were examined for their capacity to exert complement-dependent cytotoxicity against a panel of human tumour cell lines. Cytotoxicity was most evident against the immunizing tumour 791T although significant reactivity was directed against other osteogenic sarcomas. In admixture, the 2 antibodies displayed synergism in their cytotoxicity although this was only demonstrable with defined ranges of antibody concentration. The cytotoxicity of these antibodies was dependent upon the use of rabbit serum as complement and no tumour-cell lysis was produced using human, guinea-pig or mouse serum complement. The more potent cytotoxic antibody failed to modify the outgrowth of 791T tumour xenografts in immunodeprived mice even though localization of antibody at the tumour site has been demonstrated (Pimm et al., 1982).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6958308      PMCID: PMC2011198          DOI: 10.1038/bjc.1982.244

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  A microassay for the detection of tumour-specific complement-dependent serum cytotoxicity against a chemically induced rat hepatoma.

Authors:  M R Price
Journal:  Transplantation       Date:  1978-04       Impact factor: 4.939

3.  Passive administration of antiserum and complement in producing anti-EL4 cytotoxic activity in the serum of C57BL-6 mice.

Authors:  W P Drake; P C Ungaro; M R Mardiney
Journal:  J Natl Cancer Inst       Date:  1973-04       Impact factor: 13.506

Review 4.  The factor VIII complex: structure and function.

Authors:  L W Hoyer
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

5.  Natural anti-tumor serum reactivity in BALB/c mice. I. Characterization and interference with tumor growth.

Authors:  S Ménard; M I Colnaghi; G D Porta
Journal:  Int J Cancer       Date:  1977-02-15       Impact factor: 7.396

6.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

Authors:  D M Herlyn; Z Steplewski; M F Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

7.  Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

Authors:  I D Bernstein; M R Tam; R C Nowinski
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

8.  Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.

Authors:  J Ritz; J M Pesando; S E Sallan; L A Clavell; J Notis-McConarty; P Rosenthal; S F Schlossman
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

9.  Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity.

Authors:  I Hellström; J P Brown; K E Hellström
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

10.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.